Phoenix Financial Ltd. grew its stake in Danaher Corporation (NYSE:DHR – Free Report) by 54.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 10,641 shares of the conglomerate’s stock after buying an additional 3,761 shares during the period. Phoenix Financial Ltd.’s holdings in Danaher were worth $2,359,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in DHR. BlackRock Inc. acquired a new position in shares of Danaher in the second quarter worth approximately $10,492,520,000. Jupiter Topco LLC bought a new stake in Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP bought a new stake in Danaher in the second quarter valued at approximately $1,287,949,000. Bank of America Corp DE acquired a new stake in Danaher during the 2nd quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc acquired a new stake in Danaher during the 2nd quarter valued at approximately $801,056,000. 79.05% of the stock is currently owned by institutional investors.
Insider Activity at Danaher
In other news, EVP Gregory Milosevich sold 2,100 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $230.62, for a total transaction of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $5,158,277.54. This trade represents a 8.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Christopher Bouda sold 7,598 shares of Danaher stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the completion of the sale, the chief accounting officer owned 9,107 shares of the company’s stock, valued at $2,136,137.92. This represents a 45.48% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 10.80% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on DHR shares. UBS Group restated a “buy” rating and set a $260.00 price target on shares of Danaher in a report on Thursday, October 22nd. Deutsche Bank reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. TD Cowen increased their price objective on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Finally, Wells Fargo & Company lowered their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $242.91.
Get Our Latest Research Report on DHR
Danaher Stock Up 0.1%
Shares of NYSE:DHR opened at $233.16 on Monday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. The business’s 50-day moving average is $222.56 and its 200-day moving average is $201.52. The company has a market capitalization of $164.04 billion, a price-to-earnings ratio of 38.16, a P/E/G ratio of 2.93 and a beta of 0.76.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, topping the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.89 earnings per share. Equities research analysts predict that Danaher Corporation will post 8.59 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Wednesday, September 30th. Danaher’s dividend payout ratio is presently 26.19%.
Danaher Profile
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
Featured Articles
- Five stocks we like better than Danaher
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
